Eli Lilly's EloraTZP Shows Greater Weight and A1C Reduction in Phase 2b Trial

Why it matters locally: Texas, with its large and diverse population, is significantly impacted by public health concerns like obesity and type 2 diabetes. The potential availability of more effective treatments could have a notable effect on the health outcomes of many Texans.

Indianapolis, IN – A new experimental drug combination, EloraTZP, developed by Eli Lilly, yielded greater weight loss and better blood sugar control than tirzepatide 15 mg alone in adults with obesity and type 2 diabetes. Researchers presented these findings from a 48-week Phase 2b study. Participants receiving EloraTZP experienced an average weight loss of up to 54.1 pounds, representing a 23.3% reduction from their initial weight. In comparison, individuals on tirzepatide 15 mg lost an average of 34.4 pounds, a 14.8% reduction. The study also showed EloraTZP's effectiveness in improving glycemic control. Participants using EloraTZP reduced their A1C levels by up to an average of 2.9%. Those in the tirzepatide 15 mg group saw an average A1C reduction of 2.4%.